BTK Inhibitor Evobrutinib Fails to Meet Primary End Points in Phase 3 EVOLUTION Trials

Results showed that evobrutinib did not produce a more superior reduction in annualized relapse rates than teriflunomide, a previously approved disease-modifying agent.

Related Keywords

Germany ,Netherlands ,Amsterdam ,Noord Holland ,National Harbor ,Maryland ,United States ,Merck Kgaa Darmstadt ,Consortium Of Multiple Sclerosis Centers ,Merck Kgaa ,Serono ,Research In Multiple Sclerosis Congress ,Merck Kga ,Research Development ,European Committee For Treatment ,Sclerosis Model ,Multiple Sclerosis Centers ,Multiple Sclerosis Congress ,Multiple Sclerosis ,Ms ,Phase 3 Trial ,